Low Dose Hyperbaric Bupivacaine and Dexmedetomidine as an Adjuvant, Caesarean Section

NCT ID: NCT03775655

Last Updated: 2019-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-01

Study Completion Date

2019-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the effectiveness of low dose scheme with dexmedetomidine as an adjuvant. Taking in consideration optimum intraoperative surgical conditions, best post-operative pain free experience, and more stable hemodynamic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cesarean Section Spinal Anesthesia Dexmedetomidine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LD-DEX

This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).

Group Type ACTIVE_COMPARATOR

Dexmedetomidine

Intervention Type DRUG

10μg dexmedetomidine will be added to the injectate to be injected intrathecally

Control group

This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

10μg dexmedetomidine will be added to the injectate to be injected intrathecally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Precedex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Full-term pregnant women
* Singleton gestation
* American Society of Anaesthesiologists (ASA) physical status classes II and I

Exclusion Criteria

* Preterm pregnancy (\<37 wks. gestation)
* Multiple gestation
* Cardiovascular disease (e.g., preeclampsia, hypertension) and the use of antihypertensive medications
* Asthma and allergy to non-steroidal anti-inflammatory drugs
* Conditions that prevent spinal anaesthesia
* Failed spinal block and conversion to general anaesthesia
* A history of established chronic pain
* Drug addiction
* A psychiatric disorder
* Inability to communicate effectively
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Menoufia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Ashraf Nasr

Assisstant Lecturer Anesthesia, Intensive care and Pain management - Faculty of Medicie - Menoufia University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mamdoh Lotfy, Prof. Dr.

Role: STUDY_CHAIR

Faculty of Medicine - Menoufia University

Safaa M Helal, Prof. Dr.

Role: STUDY_CHAIR

Faculty of Medicine - Menoufia University

Wesameldin A Soltan, Dr.

Role: STUDY_DIRECTOR

Faculty of Medicine - Menoufia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Menoufia University Hospitals

Shibīn al Kawm, Menoufia, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9076411

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.